Indeed, data from two clinical Ib/II trials, NCT03072043 and NCT03588078, indicated a strong synergy of APR246 and 5Aza in MDS and AML patients carrying a mutant P53 protein, with the NCT03072043 study reporting an overall and complete remission rate of 86% and 53%, respectively [94]. This evidence concerns the gene TP53 and myelodysplastic syndrome.